Home > Insider Trading > Synageva Biopharma Corp

Synageva Biopharma Corp (GEVA)

Market is closed

Get Email Alerts

Profile
Hedge Fund Holdings
Insider Purchases
Insider Sales
Institutional Holdings
13 D/G Filings
News

Get Email Alerts

News

1 - 10
Next >>

Synageva Biopharma Corp (GEVA) Acquisition Helps Baker Bros. Advisors Top All Others In Q2 Returns

With the rapid pace of M&A happening in the biotechnology sector, Julian Baker and Felix Baker's Baker Bros. Advisors is making a habit of hitting home runs in 2015.

Keep Reading →

July 10th, 2015 - Hedge Funds News

Baker Bros. Advisors Hits the Jackpot with Pharmacyclics Inc (PCYC) Sale; Incyte Corporation (INCY) Among Fund’s Other Top Picks

Julian Baker and Felix Baker's Baker Bros. Advisors’ top pick from the end of 2014 has paid off for the fund in a big way in 2015.

Keep Reading →

March 5th, 2015 - Hedge Funds News

Felix Baker Raises Stake in Synageva BioPharma Corp (GEVA) Through Convention of Options

As a new form 4 filing with the Securities and Exchange Commission showed, Julian and Felix Bakers' Baker Bros Advisors, a fund focused on the biotechnology and healthcare companies, have revealed upping...

Keep Reading →

June 25th, 2014 - Hedge Funds News

Baker Bros. Strengthens Position in Seattle Genetics, Inc. (SGEN)

Julian Baker and Felix Baker have increased their exposure to Seattle Genetics, Inc. (NASDAQ:SGEN) even higher.

Keep Reading →

December 17th, 2013 - Hedge Funds News

Make Insider Trading Work For You -- Without Going To Jail

Billionaires go to jail for it. Money managers have fled the country and faked suicides when it's suggested.

Keep Reading →

October 24th, 2013 - Insider Trading News

The 'Smart Money' Loves The 500% Upside On This Biopharma Stock

Orphan drugs, those treating rare conditions for small segments of the population, do not normally get much attention compared with the likes of a $12.9 billion Lipitor -- but their approval by regulators...

Keep Reading →

October 11th, 2013 - Hedge Funds News

Is Synageva BioPharma a Buy? Baker Bros. Thinks So

Is Synageva BioPharma a buy? Baker Bros. Advisors, a hedge fund managed by Julian and Felix Baker with a focus on biotechnology, increased its stake in Synageva BioPharma Corp (NASDAQ:GEVA) today.

Keep Reading →

September 27th, 2013 - Hedge Funds News